ArticleCardiovascular and interventional radiology2026
Low-Dose Versus High-Dose Drug-Coated Balloon After Jetstream Atherectomy for Severely Calcified Femoropopliteal Lesions: A Multicenter Registry Study.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeJetstream atherectomy is commonly used to prepare severely calcified femoropopliteal lesions; however, the optimal choice between low- and high-dose drug-coated balloons after atherectomy remains unclear. MATERIALS AND
methodsWe analyzed data from multicenter JOKER registry. We identified patients with symptomatic lower-extremity artery disease who underwent Jetstream atherectomy followed by DCB angioplasty for severely calcified femoropopliteal lesions between November 2022 and December 2024. Patients were classified into the low-dose drug-coated balloon group, treated with Ranger, and the high-dose drug-coated balloon group, treated with IN.PACT Admiral. Propensity score matching was used for adjustment for clinical and lesion characteristics. The primary endpoint was 1-year primary patency.
resultsOf 219 patients, 136 were treated with low-dose drug-coated balloon and 83 with high-dose drug-coated balloon. Propensity score matching generated 66 matched pairs. In the matched cohort, flow impairment after Jetstream atherectomy did not differ significantly between the low-dose and high-dose drug-coated balloon groups (16.7% vs. 12.1%, p = 0.62). Final angiography showed preserved distal flow (100% vs. 98.4%, p > 0.99). At 1 year, primary patency did not differ significantly between the low-dose drug-coated balloon and high-dose drug-coated balloon groups (88.0% vs. 85.7%, p = 0.72). Freedom from clinically driven target lesion revascularization (94.7% vs. 92.7%, p = 0.71) and amputation-free survival (90.0% vs. 87.8%, p = 0.79) did not differ between groups.
conclusionsNo statistically significant differences in angiographic or 1-year clinical outcomes were observed between low-dose and high-dose drug-coated balloons in propensity score-matched patients.
Indexed as
Identifiers
42675265What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.